Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 25, 2026, 9:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 65 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Stage IV High Grade B-Cell Lymphoma Clear all
Terminated Phase 1Phase 2 Interventional Results available

Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors

NCT00788125
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer, Liver Cancer, Lymphoma, Neuroblastoma, Ovarian Cancer, Sarcoma, Testicular Germ Cell Tumor, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
carboplatin, dasatinib, etoposide phosphate, ifosfamide, microarray analysis, western blotting, immunohistochemistry staining method, laboratory biomarker analysis, therapeutic conventional surgery, radiation therapy
Drug · Genetic · Other + 2 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
1 Year to 25 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2022
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 13, 2023 · Synced Jun 25, 2026, 9:59 AM EDT
Recruiting Phase 2 Interventional

A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma

NCT06736613
View directory record Official record
Conditions
Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Stage III High Grade B-Cell Lymphoma, Stage IV High Grade B-Cell Lymphoma, DLBCL - Diffuse Large B Cell Lymphoma, Intravascular Large B-Cell Lymphoma, Diffuse Large B Cell Lymphoma of Breast, Diffuse Large B Cell Lymphoma of Testis, HIV-associated Diffuse Large B Cell Lymphoma, Double Expressor DLBCL
Interventions
Cerebral Spinal Fluid ctDNA
Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Jun 25, 2026, 9:59 AM EDT
Completed Phase 1 Interventional

Carmustine, Etoposide, Cyclophosphamide, and Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma

NCT00641381
View directory record Official record
Conditions
Lymphoma
Interventions
carmustine, cyclophosphamide, etoposide, pharmacological study, autologous hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
Drug · Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
10 Years to 60 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Jun 25, 2026, 9:59 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma

NCT05025800
View directory record Official record
Conditions
Aggressive B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular Lymphoma, Ann Arbor Stage III Marginal Zone Lymphoma, Ann Arbor Stage IV Grade 1 Follicular Lymphoma, Ann Arbor Stage IV Grade 2 Follicular Lymphoma, Ann Arbor Stage IV Grade 3 Follicular Lymphoma, Ann Arbor Stage IV Marginal Zone Lymphoma, Composite Lymphoma, Indolent B-Cell Non-Hodgkin Lymphoma, Refractory Aggressive B-Cell Non-Hodgkin Lymphoma, Refractory Follicular Lymphoma, Refractory Grade 3b Follicular Lymphoma, Refractory High Grade B-Cell Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Marginal Zone Lymphoma, Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma, Richter Syndrome
Interventions
CD47 Antagonist ALX148, Lenalidomide, Rituximab
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Jun 25, 2026, 9:59 AM EDT
Completed Phase 3 Interventional

Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment

NCT00008359
View directory record Official record
Conditions
Cancer
Interventions
caspofungin acetate, liposomal amphotericin B
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 17, 2013 · Synced Jun 25, 2026, 9:59 AM EDT
Completed Phase 2 Interventional

Immunotherapy in Treating Patients Who Are Undergoing Bone Marrow or Peripheral Stem Cell Transplantation

NCT00002673
View directory record Official record
Conditions
Cancer
Interventions
infection prophylaxis and management
Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
12 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2002
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 16, 2010 · Synced Jun 25, 2026, 9:59 AM EDT
Completed Phase 1 Interventional

Stem Cell Transplantation in Treating Patients With Hematologic Cancer

NCT00004904
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous/Nonmalignant Condition, Small Intestine Cancer
Interventions
anti-thymocyte globulin, filgrastim, cladribine, cyclophosphamide, etoposide, methylprednisolone, tacrolimus, allogeneic bone marrow transplantation, in vitro-treated peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Northwestern University
Other
Eligibility
Up to 45 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2000
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 3, 2012 · Synced Jun 25, 2026, 9:59 AM EDT
Completed Phase 2 Interventional Results available

Rituximab, Cyclophosphamide, and Pegfilgrastim in Treating Patients With Leukemia or Non-Hodgkin's Lymphoma

NCT00278161
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
Pegfilgrastim, Rituximab, Cyclophosphamide
Biological · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 70 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 4, 2018 · Synced Jun 25, 2026, 9:59 AM EDT
Completed Phase 2 Interventional

Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease

NCT00005613
View directory record Official record
Conditions
Lymphoma
Interventions
cyclophosphamide, etoposide, BCNU
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
15 Years to 55 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2010
U.S. locations
2
States / cities
Fort Myers, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 3, 2013 · Synced Jun 25, 2026, 9:59 AM EDT
Completed Phase 2 Interventional

Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

NCT00003402
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
carmustine, cisplatin, cyclophosphamide, dexamethasone, etoposide, melphalan, paclitaxel, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation
Drug · Procedure
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2019 · Synced Jun 25, 2026, 9:59 AM EDT
Withdrawn Phase 2 Interventional

Combination Chemotherapy Plus Interferon Alfa or Rituximab in Treating Patients With Stage III or Stage IV Lymphoma

NCT00004039
View directory record Official record
Conditions
Lymphoma
Interventions
recombinant interferon alfa, rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate
Biological · Drug
Lead sponsor
Hoag Memorial Hospital Presbyterian
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2000
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Aug 18, 2015 · Synced Jun 25, 2026, 9:59 AM EDT
Completed Phase 3 Interventional

Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation

NCT00003883
View directory record Official record
Conditions
Cancer
Interventions
fluconazole, itraconazole
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
13 Years and older
Enrollment
578 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 1, 2010 · Synced Jun 25, 2026, 9:59 AM EDT
Completed Not applicable Interventional

Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic Cancer

NCT00296023
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
anti-thymocyte globulin, filgrastim, therapeutic allogeneic lymphocytes, busulfan, fludarabine phosphate, methotrexate, tacrolimus, nonmyeloablative allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2008
U.S. locations
2
States / cities
Berkeley, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 3, 2012 · Synced Jun 25, 2026, 9:59 AM EDT
Terminated Phase 1 Interventional

Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant

NCT00725062
View directory record Official record
Conditions
Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
CD4+CD25+ regulatory T cells, allogeneic hematopoietic stem cell transplantation
Biological · Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 70 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 28, 2017 · Synced Jun 25, 2026, 9:59 AM EDT
Completed Phase 2 Interventional

Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer

NCT00003408
View directory record Official record
Conditions
Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Neuroblastoma, Ovarian Cancer, Sarcoma, Testicular Germ Cell Tumor
Interventions
aldesleukin, recombinant interferon alfa, sargramostim
Biological
Lead sponsor
Cancer Treatment Centers of America
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2000
U.S. locations
1
States / cities
Zion, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 25, 2013 · Synced Jun 25, 2026, 9:59 AM EDT
Completed Phase 2 Interventional

Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic Cancer

NCT00004061
View directory record Official record
Conditions
Leukemia, Lymphoma, Oral Complications
Interventions
filgrastim, palifermin, cyclophosphamide, etoposide, ifosfamide, peripheral blood stem cell transplantation, quality-of-life assessment, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 25, 2013 · Synced Jun 25, 2026, 9:59 AM EDT
Not listed Phase 2 Interventional

Combination Chemotherapy Plus Rituximab in Treating Patients With Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma

NCT00005959
View directory record Official record
Conditions
Lymphoma
Interventions
filgrastim, rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
27
States / cities
Montgomery, Alabama • Little Rock, Arkansas • Burbank, California + 24 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2013 · Synced Jun 25, 2026, 9:59 AM EDT
Completed Phase 1 Interventional

DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas

NCT00004212
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
filgrastim, exatecan mesylate
Biological · Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
Up to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
4
States / cities
New York, New York • Memphis, Tennessee • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated May 15, 2012 · Synced Jun 25, 2026, 9:59 AM EDT
Completed Phase 3 Interventional

Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation

NCT00014391
View directory record Official record
Conditions
Cancer
Interventions
palivizumab, ribavirin
Biological · Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 1, 2010 · Synced Jun 25, 2026, 9:59 AM EDT
Active, not recruiting Phase 1 Interventional

Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma

NCT04323956
View directory record Official record
Conditions
Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage III Marginal Zone Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Follicular Lymphoma, Ann Arbor Stage IV Marginal Zone Lymphoma, Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Indolent Non-Hodgkin Lymphoma
Interventions
Cyclophosphamide, Doxorubicin Hydrochloride, Parsaclisib, Pegfilgrastim, Polatuzumab Vedotin, Prednisone, Rituximab, Vincristine Sulfate
Drug · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 1, 2026 · Synced Jun 25, 2026, 9:59 AM EDT
Completed Not applicable Interventional Results available

Immune Reconstitution After Autologous Hematopoietic Stem Cell Transpl for High-Risk Lymphoma

NCT00569309
View directory record Official record
Conditions
Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Small Intestine Cancer
Interventions
Streptococcus pneumoniae, laboratory correlative studies, quality-of-life assessment
Biological · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 11, 2018 · Synced Jun 25, 2026, 9:59 AM EDT
Not listed Phase 1 Interventional

Emergency Use of Donor Lymphocytes in Treating Patients Who Have Undergone Donor Stem Cell Transplant and Have Cytomegalovirus Infections

NCT00769613
View directory record Official record
Conditions
Cancer
Interventions
cytomegalovirus IE-1-specific cytotoxic T lymphocytes, cytomegalovirus pp65-specific cytotoxic T lymphocytes, therapeutic allogeneic lymphocytes, polymerase chain reaction, flow cytometry, immunological diagnostic method, laboratory biomarker analysis
Biological · Genetic · Other
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
2 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 17, 2013 · Synced Jun 25, 2026, 9:59 AM EDT
Completed Phase 2 Interventional Results available

Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer

NCT00049504
View directory record Official record
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Burkitt Lymphoma, Childhood Chronic Myelogenous Leukemia, Childhood Myelodysplastic Syndromes, Childhood Nasal Type Extranodal NK/T-cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, de Novo Myelodysplastic Syndromes, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hematopoietic/Lymphoid Cancer, Hepatosplenic T-cell Lymphoma, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Peripheral T-cell Lymphoma, Post-transplant Lymphoproliferative Disorder, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Recurrent/Refractory Childhood Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Multiple Myeloma, Relapsing Chronic Myelogenous Leukemia, Secondary Myelodysplastic Syndromes, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Stage II Multiple Myeloma, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Adult T-cell Leukemia/Lymphoma, Stage III Childhood Hodgkin Lymphoma, Stage III Chronic Lymphocytic Leukemia, Stage III Cutaneous T-cell Non-Hodgkin Lymphoma, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Multiple Myeloma, Stage III Mycosis Fungoides/Sezary Syndrome, Stage III Small Lymphocytic Lymphoma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Adult T-cell Leukemia/Lymphoma, Stage IV Childhood Hodgkin Lymphoma, Stage IV Chronic Lymphocytic Leukemia, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Mycosis Fungoides/Sezary Syndrome, Stage IV Small Lymphocytic Lymphoma, Testicular Lymphoma, Waldenström Macroglobulinemia
Interventions
cyclophosphamide, fludarabine phosphate, tacrolimus, mycophenolate mofetil, polymerase chain reaction, fluorescence in situ hybridization, polymorphism analysis, gene expression analysis, total-body irradiation, allogeneic bone marrow transplantation, allogeneic hematopoietic stem cell transplantation
Drug · Genetic · Radiation + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2014
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 16, 2017 · Synced Jun 25, 2026, 9:59 AM EDT
Completed Phase 1 Interventional

Interleukin-12 in Treating Patients With Hematologic Cancers or Solid Tumors

NCT00003107
View directory record Official record
Conditions
Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions
recombinant interleukin-12
Biological
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 9, 2014 · Synced Jun 25, 2026, 9:59 AM EDT